Pfizer's heart med Vyndaqel off and running thanks to diagnosis push: execs

Early in its launch for rare heart disease meds Vyndaqel and Vyndamax, Pfizer is fielding an awareness and diagnosis push that's paying off big-time. Thousands of patients have been diagnosed, sales have mounted to almost a half-billion dollars—and much more opportunity's yet to come, execs said Tuesday.